Abstract
Immune suppression and disturbances of normal leukocyte populations are side effects attributed to many antimalarial drugs and were concerns during a recent year-long placebo-controlled trial that compared daily primaquine (0.5 mg of base per kg of body weight per day) with weekly chloroquine (300 mg of base one time per week) for malaria prophylaxis. The study took place in Irian Jaya, Indonesia, from July 1994 to August 1995 and enrolled 129 Javanese men with normal glucose-6-phosphate dehydrogenase function. Tests for lymphocyte function and subset composition were conducted blindly on a cross-section of subjects during weeks 10 (n = 42) and 48 (n = 72) of supervised prophylaxis. Lymphocyte function, measured as the proliferative response of peripheral blood mononuclear cells to a panel of mitogens (pokeweed mitogen, phytohemagglutinin, and concanavalin A) and antigens (purified protein derivative of Mycobacterium tuberculosis and Clostridium tetani toxoid) and expressed as a stimulation index, allowed for statistical comparison between groups and sampling times. The lymphocyte subset composition for each group and time point was based on flow cytometry profiling, and the results were expressed as the mean percentages of CD3 (total T cells), CD19 (total B cells), CD4+ (T-helper and inducer cells), and CD8+ (T suppressor and cytotoxic cells), CD3/CD16+ CD56 (natural killer cells), CD3/anti-HLA-DR (activated T cells) cells and the CD4+/CD8+ ratios. Lymphocyte stimulation indices were statistically comparable among the placebo, primaquine, and chloroquine groups at both time points, although the primaquine group was distinguished by having repeatedly greater proportions of subjects with high ( > 3.0) stimulation indices. The lymphocyte subset profiles of these groups at both time points were also similar and undistorted relative to those of healthy reference populations matched for age, sex, and ethnicity. The results provide quantitative support for the safety of daily primaquine prophylaxis.
Full Text
The Full Text of this article is available as a PDF (218.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baird J. K., Fryauff D. J., Basri H., Bangs M. J., Subianto B., Wiady I., Purnomo, Leksana B., Masbar S., Richie T. L. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1995 Jun;52(6):479–484. doi: 10.4269/ajtmh.1995.52.479. [DOI] [PubMed] [Google Scholar]
- Bennett S., Riley E. M. The statistical analysis of data from immunoepidemiological studies. J Immunol Methods. 1992 Feb 5;146(2):229–239. doi: 10.1016/0022-1759(92)90232-i. [DOI] [PubMed] [Google Scholar]
- CLAYMAN C. B., ARNOLD J., HOCKWALD R. S., YOUNT E. H., Jr, EDGCOMB J. H., ALVING A. S. Toxicity of primaquine in Caucasians. J Am Med Assoc. 1952 Aug 23;149(17):1563–1568. doi: 10.1001/jama.1952.72930340022010b. [DOI] [PubMed] [Google Scholar]
- Clyde D. F. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ. 1981;59(3):391–395. [PMC free article] [PubMed] [Google Scholar]
- EDGCOMB J. H., ARNOLD J., YOUNT E. H., Jr, ALVING A. S., EICHELBERGER L., JEFFERY G. M., EYLES D., YOUNG M. D. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950 Dec;9(4):285–292. [PubMed] [Google Scholar]
- Frischer H., Ahmad T., Nora M. V., Carson P. E., Sivarajan M., Mellovitz R., Ptak L., Parkhurst G. W., Chow H. S., Kaizer H. Biotransformation of primaquine in vitro with human K562 and bone marrow cells. J Lab Clin Med. 1987 Apr;109(4):414–421. [PubMed] [Google Scholar]
- Fryauff D. J., Baird J. K., Basri H., Sumawinata I., Purnomo, Richie T. L., Ohrt C. K., Mouzin E., Church C. J., Richards A. L. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet. 1995 Nov 4;346(8984):1190–1193. doi: 10.1016/s0140-6736(95)92898-7. [DOI] [PubMed] [Google Scholar]
- HURVITZ D., HIRSCHHORN K. SUPPRESSION OF IN VITRO LYMPHOCYTE RESPONSES BY CHLOROQUINE. N Engl J Med. 1965 Jul 1;273:23–26. doi: 10.1056/NEJM196507012730105. [DOI] [PubMed] [Google Scholar]
- Mihaly G. W., Ward S. A., Edwards G., Orme M. L., Breckenridge A. M. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol. 1984 Apr;17(4):441–446. doi: 10.1111/j.1365-2125.1984.tb02369.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Salmeron G., Lipsky P. E. Immunosuppressive potential of antimalarials. Am J Med. 1983 Jul 18;75(1A):19–24. doi: 10.1016/0002-9343(83)91266-4. [DOI] [PubMed] [Google Scholar]
- Thong Y. H., Ferrante A., Rowan-Kelly B. Primaquine inhibits mitogen-induced human lymphocyte proliferative responses. Trans R Soc Trop Med Hyg. 1978;72(5):537–539. doi: 10.1016/0035-9203(78)90181-5. [DOI] [PubMed] [Google Scholar]
- Ward S. A., Mihaly G. W., Edwards G., Looareesuwan S., Phillips R. E., Chanthavanich P., Warrell D. A., Orme M. L., Breckenridge A. M. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol. 1985 Jun;19(6):751–755. doi: 10.1111/j.1365-2125.1985.tb02710.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weiss W. R., Oloo A. J., Johnson A., Koech D., Hoffman S. L. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis. 1995 Jun;171(6):1569–1575. doi: 10.1093/infdis/171.6.1569. [DOI] [PubMed] [Google Scholar]